Allogene Therapeutics (ALLO) Total Liabilities: 2019-2025
Historic Total Liabilities for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $124.4 million.
- Allogene Therapeutics' Total Liabilities fell 0.74% to $124.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.4 million, marking a year-over-year decrease of 0.74%. This contributed to the annual value of $126.5 million for FY2024, which is 3.12% down from last year.
- As of Q3 2025, Allogene Therapeutics' Total Liabilities stood at $124.4 million, which was down 1.26% from $126.0 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Total Liabilities registered a high of $158.1 million during Q1 2023, and its lowest value of $102.9 million during Q2 2021.
- Its 3-year average for Total Liabilities is $132.3 million, with a median of $126.5 million in 2024.
- Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 44.92% in 2022, then decreased by 20.96% in 2024.
- Quarterly analysis of 5 years shows Allogene Therapeutics' Total Liabilities stood at $125.6 million in 2021, then climbed by 23.14% to $154.7 million in 2022, then decreased by 15.57% to $130.6 million in 2023, then fell by 3.12% to $126.5 million in 2024, then decreased by 0.74% to $124.4 million in 2025.
- Its Total Liabilities stands at $124.4 million for Q3 2025, versus $126.0 million for Q2 2025 and $122.6 million for Q1 2025.